- ≥99% HPLC purity
- Lot-matched certificate of analysis
- Ships next business day, tracked
Metabolic & Circadian Compounds
Rapamycin (Sirolimus) — Research Grade
Macrolide mTOR inhibitor — prescription-only reference listing
- Mol. weight914.17 g/mol
Supplied for laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Overview
Prescription-only reference listing. Rapamycin, known generically as sirolimus, is a prescription medicine. It appears in this institutional catalogue as a reference entry so that laboratories and clinics can identify the compound, its chemistry and its regulatory status. It is supplied only against a valid prescription or institutional authorisation, and no sourcing, dosing or administration guidance is provided here.
Specifications
Identity
- CAS number
- 53123-88-9
- Molecular formula
- C51H79NO13
- Molecular weight
- 914.17 g/mol
Supply & purity
- Solubility
- Practically insoluble in water; soluble in ethanol, methanol and DMSO
Additional detail
- Regulatory status
- Prescription-only medicine (Rx); supplied solely against valid prescription or institutional authorisation
- Generic name
- Sirolimus
- Also known as
- Rapamycin, RAPA, AY-22989
- Chemical class
- 31-membered macrocyclic lactone (macrolide) natural product
- Natural source
- Streptomyces hygroscopicus
- Molecular target
- FKBP12; the rapamycin–FKBP12 complex inhibits mTOR complex 1
- Drug class
- mTOR inhibitor; immunosuppressant
- Reference options listed
- 1 mg × 30 capsules, 5 mg × 30 capsules
- Storage
- Per the approved product labelling — original sealed container, protected from light; oral solution requires refrigeration
- Intended use
- Reference listing only; dispensed exclusively against valid authorisation
Questions about Rapamycin (Sirolimus) — Research Grade
Is rapamycin available without a prescription?
No. Sirolimus is a prescription-only medicine. This page is a reference listing in an institutional catalogue, describing the compound and its regulatory status. Product is supplied only against a valid prescription or documented institutional authorisation, and no sourcing route is offered here.
How does rapamycin inhibit mTOR?
Indirectly. It first binds the cytosolic immunophilin FKBP12, and that rapamycin–FKBP12 complex binds the FRB domain of mTOR, allosterically inhibiting mTOR complex 1. Signalling through S6 kinase 1 and 4E-BP1 falls and autophagy is induced. mTOR complex 2 is largely insensitive to acute exposure.
Why is it grouped with NMN and metformin in this catalogue?
Purely by research theme: all three are frequently discussed in the nutrient-sensing and aging-biology literature. The grouping reflects shared subject matter in published research, not a recommendation to combine them, and rapamycin's prescription status is unaffected by that grouping.
Do you provide dosing information?
No. Dosing, monitoring and administration for a prescription medicine are determined by the prescribing clinician using the approved labelling. This listing is limited to chemistry, mechanism, regulatory status and storage facts.
Related
